Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecasts, 2027 - ResearchAndMarkets.com

June 13, 2018

DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Key Topics Covered:

1. Key Insights

2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

6. Treatment Algorithm

7. Unmet Needs

8. Marketed Drugs

9. Marketed Drugs by Companies

10. Safety and Efficacy of Marketed Drugs

11. Emerging Therapies

12. Global Market Size of Pulmonary Arterial Hypertension (PAH)

13. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

14. Pulmonary Arterial Hypertension (PAH): Market Outlook by Region

15. United States

16. EU5 Countries

17. Rest of World (ROW)

18. Rest of Europe (ROE)

19. Market Drivers

20. Market Barriers

21. Appendix

22. Capabilities

Companies Mentioned

United Therapeutics Corporation Actelion Pharmaceuticals Ltd. GSK Bayer AG Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/prfvwq/pulmonary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006233/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/13/2018 04:58 PM/DISC: 06/13/2018 04:58 PM


Update hourly